1. Home
  2. LGI vs TNXP Comparison

LGI vs TNXP Comparison

Compare LGI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGI

Lazard Global Total Return and Income Fund

HOLD

Current Price

$18.04

Market Cap

226.3M

Sector

N/A

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$17.18

Market Cap

194.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGI
TNXP
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.3M
194.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LGI
TNXP
Price
$18.04
$17.18
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$70.00
AVG Volume (30 Days)
41.1K
506.0K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
7.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,299,000.00
Revenue This Year
N/A
$2.96
Revenue Next Year
N/A
$750.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.66
$6.76
52 Week High
$16.68
$69.97

Technical Indicators

Market Signals
Indicator
LGI
TNXP
Relative Strength Index (RSI) 65.45 53.17
Support Level $17.73 $14.97
Resistance Level $18.02 $17.07
Average True Range (ATR) 0.20 0.99
MACD 0.04 0.16
Stochastic Oscillator 92.80 83.72

Price Performance

Historical Comparison
LGI
TNXP

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: